title: [Heart failure: new insights and developments].
authors.affiliation: Universitätsklinik und Poliklinik für Innere Medizin III, Universitätsklinikum Halle (Saale), Halle (Saale).
authors.forename: M
authors.initials: M
authors.lastname: Hundertmark
authors.affiliation: Universitätsklinik und Poliklinik für Innere Medizin III, Universitätsklinikum Halle (Saale), Halle (Saale).
authors.forename: S
authors.initials: S
authors.lastname: Frantz
mesh_terms: D000208:Acute Disease; D000613:Aminobutyrates / Q000627:therapeutic use; D001713:Biphenyl Compounds; D058406:Cardiac Resynchronization Therapy; D003131:Combined Modality Therapy; D004338:Drug Combinations; D054144:Heart Failure, Diastolic / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D054143:Heart Failure, Systolic / Q000175:diagnosis / Q000401:mortality / Q000628:therapy*; D006801:Humans; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D011994:Recombinant Proteins / Q000627:therapeutic use; D012065:Relaxin / Q000627:therapeutic use; D013148:Spironolactone / Q000627:therapeutic use; D015996:Survival Rate; D013777:Tetrazoles / Q000627:therapeutic use; D000068756:Valsartan
chemical_list: D000613:Aminobutyrates; D001713:Biphenyl Compounds; D004338:Drug Combinations; D011994:Recombinant Proteins; D013777:Tetrazoles; C577649:serelaxin protein, human; D013148:Spironolactone; D000068756:Valsartan; D012065:Relaxin; C549068:sacubitril and valsartan sodium hydrate drug combination